Site Editor

William J. Gradishar, MD, FACP, FASCO


Peter Schmid, MD, PhD, on Clinical Implications of New Data on Pembrolizumab Plus Chemotherapy for TNBC

Posted: Monday, January 22, 2024

Peter Schmid, MD, PhD, of Queen Mary University of London, discusses the clinical implications of recent phase III findings from the KEYNOTE-522 trial on the use of pembrolizumab plus chemotherapy for patients with early-stage triple-negative breast cancer, including data on toxicities and overall survival.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.